{"organizations": [], "uuid": "14eab80309ad4aebbabbe389d92cb065b8d39171", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "news.morningstar.com", "main_image": "", "site_section": "http://news.morningstar.com/all/dow-jones/technology.aspx", "section_title": "News Archive: Technology", "url": "http://news.morningstar.com/all/dow-jones/technology/2015101513313/csl-catches-cold-from-flu-vaccines-deal-with-novartis-market-talk.aspx", "country": "US", "title": "CSL Catches Cold from Flu Vaccines Deal with Novartis -- Market Talk", "performance_score": 0, "site": "morningstar.com", "participants_count": 1, "title_full": "CSL Catches Cold from Flu Vaccines Deal with Novartis -- Market Talk", "spam_score": 0.0, "site_type": "news", "published": "2015-10-15T03:00:00.000+03:00", "replies_count": 0, "uuid": "14eab80309ad4aebbabbe389d92cb065b8d39171"}, "author": "morningstar.com", "url": "http://news.morningstar.com/all/dow-jones/technology/2015101513313/csl-catches-cold-from-flu-vaccines-deal-with-novartis-market-talk.aspx", "ord_in_thread": 0, "title": "CSL Catches Cold from Flu Vaccines Deal with Novartis -- Market Talk", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "23:08 GMT [Dow Jones] CSL (CSL.AU), Australia's largest pharmaceuticals group, is nursing a cold from the flu-vaccines business it bought from Novartis in a deal that completed in August. CSL signaled a US$130 million underlying net loss on the business in FY16, contributing to Goldman Sachs lowering its FY16-FY18 EPS forecasts by 1%-6%. Still, the broker retains a buy call on the stock. \"We believe investors will likely regards FY17 metrics as a better reflection of the company's underlying earnings (whereas FY16 incorporates flu losses ahead of the restructuring program),\" analyst Ian Abbott says. CSL last traded at A$88.99. (david.winning@wsj.com; @dwinningWSJ)\n 15, 2015 19:22 ET (23:22 ", "external_links": ["http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Checked.gif", "http://s7.addthis.com/static/btn/sm-share-en.gif", "http://www.addthis.com/bookmark.php?v=250", "http://im.mstar.com/Im/Mbr/Form_PremCheckbox_Unchecked.gif"], "published": "2015-10-15T03:00:00.000+03:00", "crawled": "2015-10-18T21:16:15.061+03:00", "highlightTitle": ""}